Pre-irradiation 9-Amino [20s] camptothecin (9-AC) in patients with newly diagnosed glioblastoma multiforme
- 56 Downloads
Purpose: To evaluate the efficacy of 9-amino [20s] camptothecin (9-AC) given before radiation therapy to patients with newly diagnosed glioblastoma multiforme (GBM). Methods: Eligible patients had newly diagnosed GBM who had residual measurable contrast-enhancing tumor. The trial was a phase 2 trial of 9-AC at 1100 μg/m2 /24 h infused over 72 h every two weeks for up to six cycles in patients with newly diagnosed GBM before radiation therapy. Results: Fourteen patients entered the study and all were evaluable. All of the patients had progressive disease by imaging criteria after at least two cycles of 9-AC (1 month). The median overall survival was 7.5 months (range 1.5–18 months). The most common adverse event was transient lymphopenia (grade 3–4). One patient developed grade 4 neutropenic fever that resolved after three days of diagnosis. Conclusions: 9-AC lacks activity against glioblastoma multiforme (GBM). Further studies looking at the efficacy of 9-AC in GBM may be futile.
Key Wordscamptothecin glioblastoma multiforme high grade astrocytomas chemotherapy
Unable to display preview. Download preview PDF.
- 2.Stupp R, Mason WP, Van Der Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10): 987–996, 2005Google Scholar
- 5.Hsiang Y, Hertyzberg R, Hecht S, Liu LF: Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I.J Biol Chem 260(27): 14873–14878, 1985Google Scholar
- 6.Hertzberg RP, Carafana MJ, Hecht SM: On the mechanism of topoisomerase I inhibition by camptothecin: Evidence for binding to an enzyme-DNA complex. Biochemistry 28(11): 4629–4638, 1989Google Scholar
- 7.Giovanella BC, Stehlin JS, Wall ME, Wani MC, Nicholas AW, Liu LF, Silber R, Potmesil M: DNA topoisomerase I–targeted chemotherapy of human colon cancer in xenografts. Science 246(4933): 1046–1048, 1989Google Scholar
- 8.Pantazis P, Hinz HR, Mendoza JT, Kozielski AJ, Williams LJ Jr, Stehlin JS Jr, Giovanella BC: Complete inhibition of growth followed by death of human malignant melanoma cells in vitro and regression of human melanoma xenografts in immunodeficient mice induced by camptothecins. Cancer Res 52(14): 3980–3987, 1992Google Scholar
- 9.Dahut W, Harold N, Takimoto C, Allegra C, Chen A, Hamilton JM, Arbuck S, Sorensen M, Grollman F, Nakashima H, Lieberman R, Liang M, Corse W, Grem J: Phase I and pharmacologic study of 9-aminocamptothecin given by 72-hour infusion in adult cancer patients. J Clin Oncol 14(4): 1236, 1996PubMedGoogle Scholar
- 13.Friedman HS, Petros WP, Friedman AH et al: Irinotecan therapy in adults with recurrent or progressive malignant glioma. Journal of Clinical Oncology 17(5): 1516–1525, 1999Google Scholar
- 14.Gruber ML, Buster WP: Temozolomide in combination with irinotecan for treatment of recurrent malignant glioma. Am J Clin Oncol 27(1): 33–38 2004Google Scholar
- 15.Crews KR, Stewart CF, Jones-Wallace D, Thompson SJ, Houghton PJ, Heideman RL, Fouladi M, Bowers DC, Chintagumpala MM, Gajjar A: Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy. Clin Cancer Res 8(7): 2202–2209, 2002Google Scholar
- 16.Macdonald D, Cairncross G, Stewart D, Forsyth P, Sawka C, Wainman N, Eisenhauer E: Phase II study of topotecan in patients with recurrent malignant glioma. National clinical Institute of Canada Clinical Trials Group. Ann Oncol 7(2): 205–207, 1996Google Scholar